3-hydroxybromazepam: bromazepam metabolite; structure given in first source
ID Source | ID |
---|---|
PubMed CID | 166774 |
SCHEMBL ID | 13585027 |
MeSH ID | M0124512 |
Synonym |
---|
bromazepam-3-hydroxy |
7-bromo-3-hydroxy-5-(2-pyridinyl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one |
3-hydroxybromazepam |
2h-1,4-benzodiazepin-2-one, 7-bromo-1,3-dihydro-3-hydroxy-5-(2-pyridinyl)- |
3-hydroxy bromazepam |
7-bromo-1,3-dihydro-3-hydroxy-5-(2-pyridinyl)-2h-1,4-benzodiazepin-2-one |
13132-73-5 |
7-bromo-3-hydroxy-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one |
56d3142v5y , |
unii-56d3142v5y |
SCHEMBL13585027 |
URRUSNGCYBXNLO-UHFFFAOYSA-N |
AKOS030241408 |
7-bromo-1,3-dihydro-3-hydroxy-5-(2-pyridyl)-2h-1,4-benzodiazepin-2-one |
DTXSID80927160 |
7-bromo-5-(pyridin-2-yl)-3h-1,4-benzodiazepine-2,3-diol |
Q21028623 |
3-hydroxybromazepam, 1mg/ml in acetonitrile |
2h-1,4-benzodiazepin-2-one, 7-bromo-1,3-dihydro-3-hydroxy-5-(2-pyridinyl)-; 2h-1,4-benzodiazepin-2-one, 7-bromo-1,3-dihydro-3-hydroxy-5-(2-pyridyl)- (8ci); 3-hydroxybromazepam; oh-bromazepam |
Excerpt | Relevance | Reference |
---|---|---|
" Antipyrine pharmacokinetics were studied immediately before bromazepam administration was started, after the dosing schedule had been completed and one week after dosing had been discontinued." | ( The effect of bromazepam (Lexotan) administration on antipyrine pharmacokinetics in humans. Allen, JG; Bird, HA; Ehsanullah, RS; Galloway, DB; Ruane, RJ, 1984) | 0.27 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (66.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.34) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |